GLP-1S can help employers cut health care costs, study star-news.press/wp

Pricing Price Prices with large GLP-1 weight loss drugs can be paid for employers by cutting overall medical consumption for people who take medication, but not up to two years, according to the huge analysis of health insurance claims Aon released on Wednesday.

Aon (Aon-0.92%)Global professional service, studied American health insurance for more than 50 million people from 2022-2024 and found that, after the initial jump in spending associated with the early injection of GLP-1 drugs such as Ozempic (NGO+ 0.71%) And the Wegovy, the cost growth for the trendy treatment group is halfway the control group in the second year.

Aon said GLP-1 beneficiaries have experienced a 44% reduction of hospitalization caused by cardiovascular events such as blows and heart attacks, as well as reduced receivables, osteoporosis and alcohol and substances.

The analysis showed more receivables from GLP-1users for arthritis, sleeping problems and thyroid disorders and esophagus. Aon theorized that the loss of weight, patients began to approach the wider range of other medical treatments.

GLP-1 medications can cost $ 12,000 a year or more, and a little insurer or employer covers the recipe costs out of diabetes, their approved uses. However, the use of GLP drugs between adults in the USA without diabetes more than tripled Between 2018. and 2022. years.

Annual drug consumption that aligned in that period of $ 1.6 billion to $ 5.8 billion. These numbers could be much bigger: ua Research from 2044. Years From 1,479 American adults, about 12% said they took GLP-1 agonist.

“When consider the indirect costs of obesity, such as the treatment of comorbidity and absence, the overall economic burden is striking,” said Farheen Dam, Aon’s Health Solutions for North America. Approximately 40% of adults are considered obese.